 The Daily Deal | Abbott's emerging entrance The Daily Deal Facet had partnered with Biogen Idec Inc. on a multiple sclerosis drug, known as daclizumab, a monoclonal antibody being considered for uses ranging from the prevention of organ rejection in transplants to treatment of multiple sclerosis. ... |
